NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
9.89
+0.12 (1.23%)
Nov 3, 2025, 1:32 PM EST - Market open
NeoGenomics Revenue
NeoGenomics had revenue of $187.80M in the quarter ending September 30, 2025, with 11.90% growth. This brings the company's revenue in the last twelve months to $709.16M, up 10.10% year-over-year. In the year 2024, NeoGenomics had annual revenue of $660.57M with 11.65% growth.
Revenue (ttm)
$709.16M
Revenue Growth
+10.10%
P/S Ratio
1.76
Revenue / Employee
$322,346
Employees
2,200
Market Cap
1.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 660.57M | 68.92M | 11.65% |
| Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
| Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
| Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
| Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
NEO News
- 4 days ago - NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors - Business Wire
- 5 days ago - NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - NeoGenomics Reports Third Quarter 2025 Results - Business Wire
- 20 days ago - NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025 - Business Wire
- 27 days ago - NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025 - Business Wire
- 6 weeks ago - NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026 - Benzinga
- 2 months ago - NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims - Benzinga
- 2 months ago - Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera - Business Wire